Growth hormone and prolactin stimulate androgen receptor, insulin-like growth factor-I (IGF-I) and IGF-I receptor levels in the prostate of immature rats.
In this study we investigated the involvement of several different pituitary hormones on rat prostate development. 22-day-old Wistar rats, hypophysectomized (hypox) at 19 days of age were supplemented with highly purified human prolactin (hPRL), human luteinizing hormone (hLH), porcine follicle-stimulating hormone (pFSH), and bovine growth hormone (bGH) or with saline. Quantitative analysis of RNAs shows that treatment with either PRL or GH increases significantly steady-state mRNAs levels of the following genes in the prostate: androgen receptor (AR) (respectively 3.5- and 4.8-fold above hypox controls), IGF-I (5- and 2.7-fold), and IGF-I receptor (2.9- and 2.3-fold). LH and FSH, by contrast, have negative effects on these parameters. To test whether the enhancing effect of PRL and GH on AR-mRNA abundance was followed by increased content in the protein itself, binding assays were performed with the androgen agonist [3H]R1881 (131 and 153 fmol/mg protein while hypox controls contained 110 fmol/mg protein). In addition to the well-documented presence of prolactin receptors in prostatic tissues, we have further demonstrated, by means of nuclease S1 protection assays plus dot- and Northern-blot analyses, that a GH receptor mRNA is produced in the immature rat prostate. Moreover, we observed not only strong lactogenic but also purely somatogenic binding to be occurring in the immature prostates. Finally, we have studied IGF-I mRNA content in separated epithelial/stromal cell fractions and have concluded that IGF-I expression is principally located in the prostatic stroma. Taken together, these results suggest that PRL and GH are involved in regulating AR synthesis, at least partially by direct action on the organ. In this context IGF-I appears as a paracrine factor playing a role in epithelium/stroma interactions during prostatic development.
Biochimie Humaine, Université de Liège, Belgium.
E
E
Reiter
P
P
Bonnet
B
B
Sente
D
D
Dombrowicz
J
J
de Leval
J
J
Closset
G
G
Hennen
D000367:Age Factors; D000818:Animals; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D013006:Growth Hormone / Q000494:pharmacology*; D007016:Hypophysectomy; D007986:Luteinizing Hormone / Q000494:pharmacology; D008297:Male; D011061:Poly A / Q000032:analysis; D011388:Prolactin / Q000494:pharmacology*; D011467:Prostate / Q000166:cytology / Q000187:drug effects* / Q000254:growth & development; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar / Q000254:growth & development / Q000378:metabolism; D011944:Receptors, Androgen / Q000096:biosynthesis / Q000187:drug effects*; D011981:Receptors, Prolactin / Q000096:biosynthesis / Q000187:drug effects; D011986:Receptors, Somatotropin / Q000096:biosynthesis / Q000187:drug effects; D013002:Somatomedins / Q000494:pharmacology*; D015854:Up-Regulation / Q000187:drug effects
D012333:RNA, Messenger; D011944:Receptors, Androgen; D011981:Receptors, Prolactin; D011986:Receptors, Somatotropin; D013002:Somatomedins; D011061:Poly A; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone